Chanda Sadiq, PA
Physician Assistant · Amherst, NYNPI 1689150690
Payments from drug & device makers
Across 135 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$431
- Lilly USA, LLC$362
- Exact Sciences$224
- Pfizer$174
- GSK$158
- Shield Therapeutics Inc$131
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,66098%
- Education$432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $431 |
| Lilly USA, LLC | 20 | $362 |
| Exact Sciences | 12 | $224 |
| Pfizer | 8 | $174 |
| GSK | 9 | $158 |
| Shield Therapeutics Inc | 8 | $131 |
| Dexcom, Inc. | 5 | $110 |
| Insulet Corporation | 5 | $101 |
| AstraZeneca | 5 | $99 |
| Amgen | 5 | $96 |
| Merck | 4 | $88 |
| Mannkind Corporation | 2 | $76 |
| Novartis | 4 | $71 |
| Johnson & Johnson | 2 | $69 |
| Astellas Pharma US Inc | 2 | $59 |
| Abbott | 2 | $56 |
| Boston Scientific | 3 | $55 |
| Sequel Med Tech, LLC | 2 | $48 |
| AbbVie | 2 | $45 |
| Ascensia Diabetes Care US Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Boehringer Ingelheim | 2 | $34 |
| Hologic Sales And Service, LLC | 1 | $25 |
| IBSA Pharma Inc. | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Cepheid | 1 | $15 |
How this compares
$2,703 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 77 | $124,588 |
| OzempicSemaglutide | 54 | $94,919 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 42 | $58,586 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $54,595 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 48 | $36,229 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 203 | $35,968 |
| TradjentaLinagliptin | 38 | $35,278 |
| MounjaroTirzepatide | 25 | $27,021 |
| Humalog Kwikpen U-100Insulin Lispro | 75 | $21,845 |
| Humulin N KwikpenInsulin Nph Human Isophane | 23 | $14,454 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $13,505 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 107 | $10,205 |
| Novolog FlexpenInsulin Aspart | 38 | $8,453 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 23 | $5,281 |
| HumalogInsulin Lispro | 15 | $4,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin N | $362 | $159,973130 claims |
| Novo NordiskOzempic | $431 | $94,91954 claims |
| Boehringer IngelheimTradjenta | $34 | $35,27838 claims |
| AbbVieSynthroid | $45 | $1,16519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Amherst
- Michael AsbachAmherst$962K
- Madeline SliszAmherst$101K
- Rachel AllenAmherst$54K
- Lauren JendraszekAmherst$40K
- Delaney FragaleAmherst$33K
- Henry YuBronx$1M
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.